10月8日，Argenx盘前跌超17%，报764.39美元/股，成交额70.88万美元。消息面上，公司宣布独立数据监测委员会建议停止efgartigimod皮下注射治疗中重度干燥综合征的三期研究，理由为无效性，研究未能达到主要终点。
尽管公司同日宣布FB102治疗乳糜泻的二期研究达到主要终点，且安全性与此前数据一致，但市场焦点仍集中于核心管线在干燥综合征适应症上的受挫。此前Argenx以22亿美元收购Forte Biosciences获得FB102，此番数据虽积极，但未能扭转投资者对短期估值承压的担忧。
Argenx SE是一家处于商业阶段的全球性生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
